Pfizer/BioNTech say COVID-19 vaccine safe in children, evokes robust immune response |
Clinical News
eMediNexus Coverage from: 
Pfizer/BioNTech say COVID-19 vaccine safe in children, evokes robust immune response

1 Read Comments                

Pfizer Inc and BioNTech SE have stated that their COVID-19 vaccine evoked a strong immune response in children aged 5 to 11 years. They further stated that they intend to seek authorization for use of the vaccine in this age group in the United States, Europe and other places as early as possible.It has been reported that the vaccine induced an immune response, in children 5 to 11 years of age, in Phase II/III clinical trial, which matched the response seen previously among 16-to-25 year olds. T...
To read the complete article ,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now